Abiraterone and Dasatinib in mCRPC

Supplemental Data

Supplemental Table 1	CTC Changes Stratified by PSA Changes				
PSA Changes from Baseline at 6 Weeks After Treatment Given	CTC Changed From Baseline in the First 6 Weeks Post-treatment (n $=$ 19)				
	Decreased (n = 7)	No Change (n = 7)	Increased (n = 5)	Decreased/No Change (n $=$ 14)	Increased (n $=$ 5)
Median, (range)	-36% (-82% to 28%)	-52% (-98% to 31%)	-30% (-94% to 14%)	-51% (-98% to 31%)	-30% (-94% to 14%)
P value	.79 ^a			.85 ^b	

Abbreviations: CTC = circulating tumor cells; PSA = prostate-specific antigen. $^a{\it P}$ value based on Kruskal-Wallis test. $^b{\it P}$ value based on Wilcoxon test.



